Ruxolitinib (Opzelura)
Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses ruxolitinib (Opzelura) 1.5% topical cream. Indication: Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Fields of Study & Subjects
melanin and skin pigmentation
Health Systems
Economic Evaluations
Quality of Life
Dermatology and Skin Diseases
Publication details
- Journal / source
- Canadian Journal of Health Technologies
- Volume
- 6
- Issue
- 2
- Publication date
- 10 February 2026
- Language
- EN